Tesla-Based Blood Pump and its Applications

2013 ◽  
Author(s):  
Choon-Sik Jhun ◽  
Ray Newswanger ◽  
Joshua Cysyk ◽  
Branka Lukic ◽  
William Weiss ◽  
...  
Keyword(s):  
Flow Distribution ◽  
Left Ventricular ◽  
Smooth Transition ◽  
State University ◽  
Ventricular Assist ◽  
Surface Areas ◽  
Nikola Tesla ◽  
Wide Range ◽  
Penn State ◽  
Related Stress

A continuous flow left ventricular assist device (LVAD) that the Penn State University has developed utilizes Tesla turbomachinery technology. Tesla pumping technology patented by Nikola Tesla in the early 20th century has multiple intriguing characteristics such as simpler manufacturing process, reduced turbulent-related stress, less cavitation due to viscous flow distribution over larger surface areas, and less hemolysis by smooth transition of fluid energy. We successfully tested the 1st version of the Penn State Tesla LVAD [1, 2]. We recently tested the 2nd version of the Tesla pump; to make the pump usable in a wide range of patients, the size of the pump was significantly reduced while trying to avoid any degradation of hemodynamic and hemolytic characteristics.

scholarly journals Factors Associated With Health‐Related Quality of Life 2 Years After Left Ventricular Assist Device Implantation: Insights From INTERMACS

2021 ◽  
Author(s):  
Kathleen L. Grady ◽  
Pariya L. Fazeli ◽  
James K. Kirklin ◽  
Salpy V. Pamboukian ◽  
Connie White‐Williams
Keyword(s):  
Heart Transplant ◽  
Left Ventricular ◽  
Short Term ◽  
Ventricular Assist ◽  
Factors Associated ◽  
Vas Score ◽  
Related Quality ◽  
Health Related ◽  
Related Stress

Background Factors related to health‐related quality of life (HRQOL) 2 years after left ventricular assist device (LVAD) implantation are unknown. We sought to determine whether preimplant intended goal of LVAD therapy (heart transplant candidate [short‐term group], uncertain heart transplant candidate [uncertain group], and heart transplant ineligible [long‐term group]) and other variables were related to HRQOL 2 years after LVAD implantation. Methods and Results Our LVAD sample (n=1620) was from INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). Using the EuroQol‐5 Dimension Questionnaire (EQ‐5D‐3L), a generic HRQOL measure, and the Kansas City Cardiomyopathy Questionnaire (KCCQ‐12), a heart failure–specific HRQOL measure, multivariable linear regression modeling was conducted with the EQ‐5D‐3L Visual Analog Scale (VAS) score and KCCQ‐12 overall summary score (OSS) as separate dependent variables. Two years after LVAD implant, the short‐term group had a significantly higher mean VAS score versus the uncertain and long‐term groups (short‐term: 75.18 [SD, 20.62]; uncertain: 72.27 [SD, 20.33]; long‐term: 70.87 [SD, 22.09], P =0.01); differences were not clinically meaningful. Two‐year mean scores did not differ by group for the KCCQ‐12 OSS (short‐term, 67.85 [SD, 20.61]; uncertain, 67.79 [SD, 19.31]; long‐term, 67.08 [SD, 21.49], P =0.80). Factors associated with a worse VAS score 2 years postoperatively (n=1205) included not working; not having a short‐term LVAD; and postoperative neurological dysfunction, greater health‐related stress, coping poorly, less VAD self‐care confidence, and less satisfaction with VAD surgery, explaining 28% of variance ( P <0.001). Factors associated with a worse KCCQ‐12 OSS 2 years postoperatively (n=1250) included not working; history of high body mass index and diabetes mellitus; and postoperative renal dysfunction, greater health‐related stress, coping poorly, less VAD self‐care confidence, less satisfaction with VAD surgery, and regret regarding VAD implantation, accounting for 36% of variance ( P <0.001). Conclusions Factors related to HRQOL 2 years after LVAD implantation include demographic, clinical, and psychological variables.

scholarly journals Improved estimation of left ventricular volume from electric field modeling

2021 ◽  
Vol 12 (1) ◽  
pp. 125-134
Author(s):  
Leonie Korn ◽  
Stephan Dahlmanns ◽  
Steffen Leonhardt ◽  
Marian Walter
Keyword(s):  
Electric Field ◽  
Analytical Calculation ◽  
Ventricular Volume ◽  
Volume Measurement ◽  
In Vitro Models ◽  
Left Ventricular ◽  
Calculation Methods ◽  
Ventricular Assist ◽  
Wide Range

Abstract Volume measurement is beneficial in left ventricular assist device (LVAD) therapy to quantify patient demand. In principle, an LVAD could provide a platform that allows bioimpedance measurements inside the ventricle without requiring additional implants. Conductance measured by the LVAD can then be used to estimate the ventricular radius, which can be applied to calculate ventricular volume. However, established methods that estimate radius from conductance require elaborate individual calibration or show low accuracy. This study presents two analytical calculation methods to estimate left ventricular radius from conductance using electric field theory. These methods build on the established method of Wei, now considering the dielectric properties of muscle and background tissue, the refraction of the electric field at the blood-muscle boundary, and the changes of the electric field caused by the measurements. The methods are validated in five glass containers of different radius. Additional bioimpedance measurements are performed in in-vitro models that replicate the left ventricle’s shape and conductive properties. The proposed analytical calculation methods estimate the radii of the containers and the in-vitro models with higher accuracy and precision than Wei’s method. The lead method performs excellently in glass cylinders over a wide range of radii (bias: 1.66%–2.48%, limits of agreement < 16.33%) without calibration to specific geometries.

Abstract 16583: Beta Blocker Administration Within 30 Days Post-Left Ventricular Assist Device Significantly Decreases 1-Year Mortality in a Multi-institutional Retrospective Cohort Study

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Mohamed H Derbala ◽  
Mercedes Rivas-Lasarte ◽  
Salil Kumar ◽  
Joel Ferrall ◽  
Matthew Cefalu ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Medical Center ◽  
Beta Blockers ◽  
Left Ventricular ◽  
Ohio State University ◽  
State University ◽  
Ventricular Assist ◽  
Medical Centers ◽  
Left Ventricular Assist ◽  
Mortality Table

Introduction: The utilization of beta blockers (BB) post LVAD implantation is controversial, especially in the setting of right ventricular failure. There is limited evidence-based data regarding the survival benefits of BB post LVAD implantation Hypothesis: We hypothesized that BB use would not be associated with increased mortality Methods: We performed a dual-center retrospective study of 487 patients from Ohio State University & Montefiore Medical Center who received a continuous-flow durable LVAD bet. Jan 2006 through Dec 2016. A survival analysis was done to determine if patients had increased 1 year mortality depending on whether they received BB within 30 days post LVAD, after 30 days & up to 1 year post LVAD, or did not receive BB. Multivariate analysis of predictors of post LVAD mortality was conducted. Results: Overall the baseline characteristics bet. the 3 groups were similar (Table 1). BB utilization within 30 days post LVAD was associated with a drastic decrease in 1 year mortality (p <0.001; Fig.1). Multivariate analysis shows that no BB use (HR 3.36, p <0.001), age ≥70 (HR 2.73, p = 0.005) & pre LVAD creatinine ≥1.5 mg/dl (HR 1.86, p = 0.022) were significant independent predictors of mortality (Table 2). Conclusions: The early use of BB significantly improves 1 year survival post LVAD. Notably these results are from Midwest and East Coast Medical Centers to improve generalizability.

Surgical Implantation Techniques of Modern Continuous Flow Ventricular Assist Devices

2021 ◽  
Author(s):  
Gaik Nersesian1,2 ◽  
Evgenij Potapov ◽  
Christoph Starck ◽  
Timo Nazari-Shafti ◽  
Markus Kofler ◽  
...  
Keyword(s):  
Continuous Flow ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Surgical Approaches ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Wide Range ◽  
Implantation Techniques ◽  
Surgical Implantation

Implantable left ventricular assist devices (durable LVADs) have dramatically improved mortality and morbidity in patients with advanced heart failure. Originally designed as a bridge or candidacy to heart transplantation, the indications extend toward permanent support and palliation. Modern durable continuous flow LVADs are small, commercially available, and allow for different surgical approaches to a wide range of patients with various cardiac pathologies. We will review different surgical implantation techniques of modern continuous flow LVADs, as well as specific aspects of preoperative patient evaluation and planning.

A Particle Image Velocimetry Study of the Penn State 50cc Left Ventricular Assist Device: The Impact of Varying Heart Rate

2011 ◽  
Author(s):  
Michael A. Navitsky ◽  
Jason C. Nanna ◽  
Stephen R. Topper ◽  
Steven Deutsch ◽  
Keefe B. Manning
Keyword(s):  
Heart Failure ◽  
Thrombus Formation ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Left Ventricular Assist Devices ◽  
Ventricular Assist ◽  
Bridge To Transplant ◽  
Left Ventricular Assist ◽  
Penn State ◽  
The Impact

Approximately 5.7 million Americans are afflicted with heart failure, with a reported 670,000 new diagnoses each year [1]. Left ventricular assist devices (LVADs) function as a bridge to transplant therapy for advanced staged heart failure patients awaiting a donor heart. A pulsatile 50cc LVAD, Figure 1, is currently under development for cardiac support of patients with limited chest cavity size. Although the 50cc LVAD is functional in assisting a failing ventricle, complications such as thrombus formation may limit long term usage.

A Correlative Study of Fluid Mechanics and Evidence of Thrombus Formation Within the Penn State 50 CC Left Ventricular Assist Device

2012 ◽  
Author(s):  
Stephen R. Topper ◽  
Michael A. Navitsky ◽  
Christopher A. Siedlecki ◽  
Steven Deutsch ◽  
Gerson Rosenberg ◽  
...  
Keyword(s):  
Thrombus Formation ◽  
Major Complication ◽  
The United States ◽  
Left Ventricular ◽  
Ventricular Assist Devices ◽  
Heart Transplants ◽  
Ventricular Assist ◽  
Bridge To Transplant ◽  
Left Ventricular Assist ◽  
Penn State

An estimated 82.6 million American adults live with one or more forms of cardiovascular disease and in past years, it was the cause of over 55% of all deaths in the United States, more than any other type of major disease [1]. With a limited number of available donors, heart transplants are seldom an option. As a result, ventricular assist devices (VADs) have become a viable alternative to immediate transplant. Today, VADs are widely used as bridge-to-recovery, bridge-to-transplant and destination therapy devices. Despite past improvements in VAD design, a major complication that continues to arise is thrombus formation within the pump.

The 50cc Penn State Left Ventricular Assist Device: A Parametric Study of Valve Orientation Flow Dynamics

ASAIO Journal ◽  
2006 ◽  
Vol 52 (2) ◽  
pp. 123-131 ◽  
Author(s):  
James W. Kreider ◽  
Keefe B. Manning ◽  
Leslie A. Oley ◽  
Arnold A. Fontaine ◽  
Steven Deutsch
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Parametric Study ◽  
Left Ventricular ◽  
Flow Dynamics ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
Penn State

scholarly journals Incidence of Pump Thrombosis in HeartMate II during Destination Therapy

2016 ◽  
Author(s):  
Rohan Samson ◽  
Abhishek Jaiswal ◽  
Frank Smart ◽  
Thierry H. LeJemtel
Keyword(s):  
Left Ventricular ◽  
Circulatory Support ◽  
Destination Therapy ◽  
Heartmate Ii ◽  
Ventricular Assist ◽  
Pump Thrombosis ◽  
Wide Range ◽  
Left Ventricular Assist ◽  
Low Incidence

Pump thrombosis occurs during destination therapy (DT) with HeartMate II, a continuous blood flow left ventricular assist device (St Jude, Pleasanton, CA, USA). With adherence to stringent post-operative and long-term anticoagulation a low incidence of pump thrombosis was initially reported during DT. The increased PT incidence during DT that was reported in early 2013 was attributed to lenient anticoagulation. A wide range of pump thrombosis incidence during DT is being reported since the return to stringent post-operative and long-term anticoagulation. We searched PubMed from January 2008 to February 2016 for reports of pump thrombosis during mechanical circulatory support with HeartMate II and focus on the incidence rate of pump thrombosis from DT approval by the Food and Drug Administration to present. Pump thrombosis which may have been initially underestimated continues to complicate DT with HeartMate II despite stringent post-operative and long-term anticoagulation.

Sign in / Sign up

Export Citation Format

Share Document